查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2100175

核醫放射性同位素市場：全球市場預測（2026-2032 年）

Nuclear Medicine Radioisotopes Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，核醫放射性同位素市場規模將成長至 134.4 億美元，年複合成長率為 9.99%。

主要市場統計數據
基準年（2025 年） 68.9億美元
預計年份（2026年） 75.5億美元
預測年份（2032年） 134.4億美元
複合年成長率（） 9.99%

核子醫學用放射性同位素：執行摘要

核醫放射性同位素是精準診斷和標靶治療的核心，使臨床醫生能夠觀察生理功能、確定疾病分期、制定治療策略，並對病變組織進行局部放射治療。此領域涵蓋用於SPECT和PET影像的診斷性放射性核種、放射性藥物治療的治療性放射性核種，以及將影​​像生物標記與個人治療診斷學治療方案結合的診療一體化（治療與診斷的融合）。推動這項需求的因素包括癌症和心血管疾病負擔的加重、PET/CT和SPECT/CT基礎設施的擴展、放射性配體療法的臨床應用日益廣泛，以及政府對醫用同位素供應穩定性的日益關注。

核子醫學放射性同位素領域的一次根本性變革。

核子醫學中放射性同位素的應用格局正在經歷一場重大轉變，從主要用於診斷轉向涵蓋診斷和治療的綜合診療模式。治療診斷治療診斷學）正在加速臨床對放射性核素對的關注，這些核素對能夠識別受體表達、確認患者合格、監測治療反應並支持個體化治療方案的選擇。這種轉變在腫瘤學領域尤其顯著，人們對放射性藥物治療、劑量測定以及在前列腺癌、神經內分泌腫瘤、甲狀腺疾病和其他適應症中的多學科核醫學工作流程的興趣日益濃厚。

人工智慧對核子醫學中所使用的放射性同位素的累積影響。

人工智慧正對核醫放射性同位素的整個價值鏈產生日益顯著的影響，從同位素規劃和放射性藥物生產到影像和治療的最佳化，無一例外。在影像領域，人工智慧驅動的重建技術能夠降低放射性、縮短掃描時間、提高病灶偵測靈敏度，並增強PET和SPECT工作流程中的定量一致性。此外，基於人工智慧的分割和放射組學正在增強疾病特徵分析、治療反應評估和患者分層，尤其是在腫瘤學和循環系統領域。

對全球核醫放射性同位素市場進行區域分析。

在亞太地區，醫院基礎設施的擴建、癌症診斷率的提高以及主要醫療中心PET/CT和SPECT系統的普及，都推動了核醫學放射性同位素的需求成長。擁有先進核子醫學計畫的國家正在加強其迴旋加速器網路和放射性藥物生產能力​​，而新興經濟體則著重於提高醫療服務可近性、人力資源開發和轉診系統。該地區擁有龐大的患者群體，對癌症診斷的投入不斷增加，且各國都高度重視發展國內放射性藥物生產能力​​，因此是未來臨床應用的關鍵樞紐。然而，基礎設施不平衡、熟練人員短缺以及同位素物流等問題仍然是亟待解決的重大障礙。

關於核醫學放射性同位素開發的主要群體特定考慮因素

鑑於核能基礎設施和跨境衛生安全的戰略重要性，北約成員國（其中許多與歐洲和北美先進的醫療保健體系重疊）日益關注關鍵醫用同位素的供應韌性、輻射安全、物流保障和業務永續營運計畫。七國集團（G7）國家透過臨床研究、完善的管理體制體系、同位素生產計畫、高品質的影像基礎設施以及早期採用放射性藥物療法，為許多先進的核醫學生態系統提供支援。在這些經濟區域內，政策關注的重點是鉬-99和Technetium-99m的供應韌性、治療性同位素的可靠取得以及創新、保險報銷和患者就醫之間的協調。

對各國核醫放射性同位素進行分析。

美國是核醫放射性同位素領域最活躍的國家之一，這得益於PET和SPECT的廣泛應用、不斷擴展的放射性配體治療項目，以及國家對國內同位素生產和供應穩定性的高度重視。加拿大在核子領域擁有悠久的歷史和豐富的經驗，在同位素科學領域發揮重要作用，同時也不斷提升基於迴旋加速器的生產能力和臨床核醫學水平。墨西哥的核子醫學活動主要集中在主要都市區，其需求受腫瘤學、循環系統以及進口或本地生產的放射性藥物供應情況的影響。巴西是拉丁美洲領先的核醫學中心之一，這得益於公共衛生需求、核子研究機構以及大都會圈診斷影像技術的日益普及。

為核子醫學放射性同位素行業的領導者提供的實用建議。

產業領導者應優先考慮緊急時應對計畫應對核子反應爐停駛、運輸中斷和監管延誤的緊急計畫，來建構具有韌性的同位素供應策略。投資於自動化放射性藥物製備系統、檢驗的品管、數位化批次追蹤和預測性庫存管理，可以減少廢棄物，並提高短半衰期放射性核素的可靠性。

用於理解核子醫學中所使用的放射性同位素的分析方法

本報告基於系統的二手研究途徑，重點關注與核醫學放射性同位素相關的檢驗、公開且有數據支持的資訊來源。該分析方法包括對臨床指南、監管指令、核能安出版刊物、放射性同位素供應文件、醫療基礎設施數據、放射性藥物標準、疾病負擔證據、同行評審文獻以及來自權威衛生、核能和科研機構的公共政策材料的審查。

結論：放射性同位素在核子醫學中的策略前景

隨著醫療保健系統從傳統診斷影像擴展到治療診斷學和標靶放射性藥物治療模式，核醫放射性同位素在現代精準醫學中變得日益重要。該領域的進展取決於可靠的同位素生產、檢驗的放射化學方法、技術精湛的臨床團隊、先進的影像基礎設施、支持性的保險報銷機制以及嚴格的輻射安全管治。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：人工智慧（AI）的累積影響（2026 年）

第7章：核醫放射性同位素市場：依同位素類型分類

  • 診斷同位素
    • 用於SPECT的同位素
      • Technetium-99m
      • 碘-123
      • 鉈-201
      • 鎵-67
      • 銦-111
    • 用於PET的同位素
      • 氟-18
      • 碳-11
      • 氮-13
      • 氧-15
      • 銣-82
      • 銅-64
  • 治療性同位素
    • BETA射線放射體
    • α粒子發射材料
    • 俄歇電子發射器
    • 用於近距離放射的同位素

第8章：核醫放射性同位素市場：依給藥方式分類

  • 靜脈注射
  • 口服

第9章：核醫放射性同位素市場：依生產技術分類

  • 核子反應爐生產
  • 迴旋加速器生產
  • 發電裝置/系統
  • 利用直線加速器（linac）進行生產

第10章：核醫放射性同位素市場：依最終用戶分類

  • 學術和研究機構
  • 診斷影像中心
  • 醫院
  • 製藥和生物技術公司

第11章 核醫放射性同位素市場：依疾病領域分類

  • 瘤
  • 循環系統疾病
  • 神經系統疾病
  • 內分泌疾病
  • 呼吸內科
  • 腎臟疾病
  • 胃腸病學
  • 感染疾病/發炎

第12章：核醫放射性同位素市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：核醫放射性同位素市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • ASEAN
  • GCC

第14章：核醫放射性同位素市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 日本
  • 印度
  • 英國
  • 法國
  • 加拿大
  • 義大利
  • 澳洲
  • 巴西
  • 韓國
  • 墨西哥
  • 俄羅斯
  • 西班牙

第15章 競爭格局

  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）

第16章：公司簡介

  • Bayer AG
  • Bracco Imaging SpA
  • BWX Technologies Inc
  • China Isotope & Radiation Corporation
  • Curium NV
  • Eckert & Ziegler SE
  • GE HealthCare Technologies Inc
  • Global Medical Solutions LLC
  • Institut National des Radioelements
  • Institute of Isotopes Co Ltd
  • International Isotopes Inc
  • Ion Beam Applications SA
  • Isotopia Molecular Imaging Ltd
  • ITM Isotope Technologies Munich SE
  • JSC Isotope
  • Jubilant Pharmova Limited
  • Lantheus Holdings Inc
  • Nordion Canada Inc
  • NorthStar Medical Radioisotopes LLC
  • Novartis AG
  • NTP Radioisotopes SOC Ltd
  • PDRadiopharma Inc
  • PharmaLogic Holdings Corp
  • RadioMedix Inc
  • SHINE Technologies LLC
  • Siemens Healthineers AG
  • SpectronRx LL
  • Telix Pharmaceuticals Limited
Product Code: MRR-742BD51821D7

The Nuclear Medicine Radioisotopes Market is projected to grow by USD 13.44 billion at a CAGR of 9.99% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.89 billion
Estimated Year [2026] USD 7.55 billion
Forecast Year [2032] USD 13.44 billion
CAGR (%) 9.99%

Nuclear Medicine Radioisotopes Executive Summary

Nuclear medicine radioisotopes are central to precision diagnostics and targeted therapy, enabling clinicians to visualize physiology, stage disease, guide treatment decisions, and deliver localized radiation to diseased tissue. The field spans diagnostic radionuclides used in SPECT and PET imaging, therapeutic radionuclides used in radiopharmaceutical therapy, and theranostic pairings that connect imaging biomarkers with personalized treatment pathways. Demand is supported by the rising burden of cancer and cardiovascular disease, expanding PET/CT and SPECT/CT infrastructure, greater clinical use of radioligand therapies, and growing government attention to medical isotope supply resilience.

The industry is also defined by complexity: short half-lives, specialized production routes, validated cold-chain logistics, radiation safety requirements, and stringent regulatory controls. Reactor-produced isotopes, cyclotron-produced isotopes, generator systems, and emerging accelerator-based production platforms each play distinct roles in supply security. As hospitals and radiopharmacies pursue reliable access to technetium-99m, fluorine-18, gallium-68, lutetium-177, iodine-131, actinium-225, and other clinically relevant isotopes, stakeholders are prioritizing redundancy, quality assurance, and closer alignment between isotope production, radiochemistry, imaging capacity, and patient referral pathways.

Transformative Shifts in the Nuclear Medicine Radioisotopes Landscape

The nuclear medicine radioisotopes landscape is undergoing a decisive shift from predominantly diagnostic utilization toward integrated diagnostic-therapeutic care models. Theranostics is accelerating clinical interest in radionuclide pairs that identify receptor expression, confirm eligibility, monitor response, and support individualized therapy selection. This shift is particularly visible in oncology, where prostate cancer, neuroendocrine tumors, thyroid disease, and other indications are driving greater attention to radiopharmaceutical therapy, dosimetry, and multidisciplinary nuclear medicine workflows.

Supply-chain transformation is equally important. The sector is moving beyond reliance on limited legacy reactor capacity toward diversified production strategies that include regional cyclotron networks, accelerator-based isotope generation, generator availability, and expanded processing capabilities. Health systems are also investing in radiopharmacy modernization, automated synthesis modules, digital inventory tracking, and waste management practices that reduce operational risk. Regulatory scrutiny, isotope purity standards, transport restrictions, and environmental considerations are influencing procurement decisions, while workforce shortages in nuclear medicine physicians, radiochemists, medical physicists, and technologists remain a practical constraint on broader clinical adoption.

Cumulative Impact of Artificial Intelligence on Nuclear Medicine Radioisotopes

Artificial intelligence is increasingly influencing the full nuclear medicine radioisotopes value chain, from isotope planning and radiopharmaceutical production to image interpretation and therapy optimization. In imaging, AI-assisted reconstruction can support lower administered activity protocols, shorter scan times, improved lesion detectability, and enhanced quantitative consistency across PET and SPECT workflows. AI-based segmentation and radiomics are also strengthening disease characterization, treatment response assessment, and patient stratification, particularly in oncology and cardiology applications.

Operationally, AI can improve production scheduling, inventory allocation, route planning, and decay management for short-lived radioisotopes. Predictive analytics may help radiopharmacies and imaging centers anticipate demand, reduce missed-dose events, and coordinate patient appointments with production and delivery windows. In therapeutic nuclear medicine, AI-enabled dosimetry, organ-at-risk modeling, and longitudinal response assessment are supporting movement toward more personalized radiopharmaceutical therapy. However, adoption depends on validated algorithms, interoperable clinical systems, high-quality imaging datasets, cybersecurity safeguards, and transparent regulatory evaluation of AI tools used in radiation-based clinical decision-making.

Key Regional Insights Across Global Nuclear Medicine Radioisotopes

In Asia-Pacific, nuclear medicine radioisotopes are supported by expanding hospital infrastructure, rising cancer diagnosis, and growing deployment of PET/CT and SPECT systems across major healthcare hubs. Countries with advanced nuclear medicine programs are strengthening cyclotron networks and radiopharmaceutical manufacturing capabilities, while emerging economies are focusing on access, training, and referral system development. The region's large patient base, increasing investment in oncology diagnostics, and national interest in domestic radiopharmaceutical capability make it a significant center for future clinical adoption, although uneven infrastructure, limited specialist workforces, and isotope logistics remain important barriers.

Europe benefits from a dense network of academic hospitals, nuclear research institutions, radiopharmacies, and regulatory frameworks that support both diagnostic nuclear medicine and theranostic innovation. The region is actively engaged in medical isotope security, clinical trial development, radiopharmaceutical standards, and cross-border coordination for supply continuity. North America demonstrates mature nuclear medicine utilization, strong clinical research activity, and established reimbursement pathways for many diagnostic and therapeutic procedures. The region has placed sustained emphasis on reducing vulnerability in molybdenum-99 and technetium-99m supply, diversifying isotope production, and expanding radioligand therapy services.

Latin America is advancing through major urban medical centers, where nuclear cardiology, oncology imaging, and selected therapeutic applications are increasingly available; however, geographic distribution, import dependence, infrastructure concentration, and public-private access gaps shape adoption patterns. Africa remains highly heterogeneous, with nuclear medicine services concentrated in select countries and urban centers; priorities include workforce development, equipment access, regional isotope logistics, radiation safety capacity, and international cooperation to expand safe and sustainable services. The Middle East is investing in tertiary care, oncology centers, and nuclear medicine infrastructure, particularly in countries prioritizing advanced specialty care, medical tourism, and national health transformation strategies.

Key Group Insights for Nuclear Medicine Radioisotope Development

NATO members, many of which overlap with advanced European and North American healthcare systems, are increasingly attentive to critical medical isotope supply resilience, radiological safety, secure logistics, and continuity planning, given the strategic importance of nuclear infrastructure and cross-border health security. The G7 countries anchor much of the advanced nuclear medicine ecosystem through clinical research, regulatory maturity, isotope production planning, high-quality imaging infrastructure, and early adoption of radiopharmaceutical therapies. Within these economies, policy attention is focused on resilient molybdenum-99 and technetium-99m supply, reliable access to therapeutic isotopes, and alignment between innovation, reimbursement, and patient access.

The European Union supports the sector through coordinated regulation, radiopharmaceutical quality standards, research funding, radiation protection frameworks, and medical isotope supply initiatives, making it a critical hub for clinical protocol development, radiochemistry expertise, and theranostic implementation. BRICS economies combine large patient populations with expanding nuclear science, healthcare infrastructure, and domestic production ambitions. These countries are relevant for isotope security because several possess reactor, cyclotron, or accelerator capabilities, although access varies widely between urban centers and rural populations and is strongly shaped by reimbursement, workforce availability, and referral networks.

ASEAN countries are strengthening nuclear medicine access through hospital modernization, cancer care expansion, and regional training initiatives, with adoption concentrated in larger metropolitan hospitals and national referral centers. The group's diversity means that advanced PET radiotracer use and radiopharmaceutical therapy are more developed in higher-income healthcare systems, while other members focus on basic SPECT imaging, equipment availability, and reliable isotope procurement. The GCC is advancing nuclear medicine radioisotopes through investment in specialized oncology centers, tertiary hospitals, and high-end diagnostic imaging capacity. Demand is reinforced by national health transformation agendas, rising noncommunicable disease burden, and efforts to reduce outbound medical travel.

Key Country Insights in Nuclear Medicine Radioisotopes

The United States is one of the most active environments for nuclear medicine radioisotopes, supported by broad PET and SPECT utilization, expanding radioligand therapy programs, and national attention to domestic isotope production and supply resilience. Canada has long-standing nuclear expertise and plays an important role in isotope science, while also advancing cyclotron-based production and clinical nuclear medicine capacity. Mexico's nuclear medicine activity is concentrated in major urban centers, with demand shaped by oncology, cardiology, and access to imported or regionally produced radiopharmaceuticals. Brazil represents one of Latin America's leading nuclear medicine settings, supported by public health demand, nuclear research institutions, and increasing use of diagnostic imaging in large metropolitan regions.

In Europe, the United Kingdom maintains strong clinical nuclear medicine services, research infrastructure, and interest in theranostics, while Germany is recognized for advanced radiopharmaceutical therapy, academic nuclear medicine, and broad imaging infrastructure. France combines hospital-based nuclear medicine with nuclear technology expertise and regulatory maturity, and Russia has significant nuclear capabilities relevant to isotope production and radiopharmaceutical development. Italy and Spain maintain well-established nuclear medicine networks, with oncology imaging, cardiology applications, and theranostic services contributing to clinical demand across major health systems.

In Asia-Pacific, China is rapidly expanding nuclear medicine infrastructure, PET imaging access, and domestic radiopharmaceutical capabilities as part of broader healthcare modernization. India is advancing through a combination of nuclear research assets, expanding cancer care needs, and growing private and public diagnostic capacity, though equitable access remains a key challenge. Japan has mature imaging infrastructure, strong clinical standards, and significant experience in nuclear medicine procedures, supported by advanced hospital systems. Australia benefits from established nuclear medicine services, isotope production expertise, and geographically important distribution planning, while South Korea continues to strengthen PET imaging, radiopharmaceutical research, and advanced oncology care within a technologically sophisticated healthcare system.

Actionable Recommendations for Nuclear Medicine Radioisotope Leaders

Industry leaders should prioritize resilient isotope supply strategies by diversifying production sources, qualifying backup suppliers, strengthening generator and cyclotron access, and improving contingency planning for reactor outages, transport disruptions, and regulatory delays. Investments in automated radiopharmacy systems, validated quality control, digital batch tracking, and predictive inventory management can reduce waste and improve reliability for short-lived radionuclides.

Clinical adoption can be accelerated by aligning radiopharmaceutical availability with scanner capacity, referral education, reimbursement readiness, and multidisciplinary care pathways involving nuclear medicine, oncology, cardiology, radiology, pharmacy, and medical physics. Organizations should also build capabilities in theranostic service delivery, including patient selection, radiation safety, dosimetry, post-therapy imaging, and adverse event monitoring. Workforce development is essential; training programs for radiochemists, technologists, physicians, physicists, and radiation safety officers should be treated as strategic infrastructure.

Leaders should adopt AI and digital tools selectively, focusing on validated use cases such as image reconstruction, quantitative analysis, scheduling, logistics, dose optimization, and therapy monitoring. Partnerships with hospitals, regulators, academic centers, isotope producers, and logistics providers can improve standardization and regional access. Sustainability should also be embedded into procurement and operations through waste reduction, optimized transport routes, safe source handling, and compliance with evolving environmental and radiological safety expectations.

Research Methodology for Nuclear Medicine Radioisotope Insights

This executive summary is developed using a structured secondary research approach focused on verified, publicly available, and data-backed sources relevant to nuclear medicine radioisotopes. The methodology includes review of clinical guidelines, regulatory communications, nuclear safety publications, isotope supply documentation, healthcare infrastructure data, radiopharmaceutical standards, disease burden evidence, peer-reviewed literature, and public policy materials from recognized health, nuclear, and scientific organizations.

The analysis evaluates production pathways, diagnostic and therapeutic applications, clinical adoption factors, regional infrastructure, regulatory considerations, logistics constraints, and technology trends without presenting market estimation, market sizing, market share, or forecasting. Insights are synthesized to identify directional patterns across regions, economic groups, and key countries, with emphasis on practical industry implications. The research approach prioritizes source credibility, cross-validation of claims, consistency with established nuclear medicine practice, and exclusion of unsupported projections or promotional assertions.

Conclusion: Strategic Outlook for Nuclear Medicine Radioisotopes

Nuclear medicine radioisotopes are becoming increasingly important to modern precision medicine as healthcare systems expand from conventional diagnostic imaging toward theranostic and targeted radiopharmaceutical therapy models. The sector's progress depends on reliable isotope production, validated radiochemistry, skilled clinical teams, advanced imaging infrastructure, supportive reimbursement, and rigorous radiation safety governance.

The most important strategic themes are supply resilience, clinical integration, regional access, and digital transformation. Regions and countries with strong nuclear infrastructure, healthcare investment, and specialist workforces are better positioned to scale advanced nuclear medicine services, while emerging markets require coordinated investment in equipment, training, logistics, and regulatory capacity. Artificial intelligence, automation, and quantitative imaging will further improve efficiency and personalization, but only when implemented with robust validation and clinical oversight. Overall, nuclear medicine radioisotopes will remain a critical enabler of disease detection, treatment planning, and targeted therapy across oncology, cardiology, neurology, endocrinology, and other high-value clinical areas.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Nuclear Medicine Radioisotopes Market, by Isotope Type

  • 7.1. Introduction
  • 7.2. Diagnostic Isotopes
    • 7.2.1. SPECT Isotopes
      • 7.2.1.1. Technetium-99m
      • 7.2.1.2. Iodine-123
      • 7.2.1.3. Thallium-201
      • 7.2.1.4. Gallium-67
      • 7.2.1.5. Indium-111
    • 7.2.2. PET Isotopes
      • 7.2.2.1. Fluorine-18
      • 7.2.2.2. Carbon-11
      • 7.2.2.3. Nitrogen-13
      • 7.2.2.4. Oxygen-15
      • 7.2.2.5. Rubidium-82
      • 7.2.2.6. Copper-64
  • 7.3. Therapeutic Isotopes
    • 7.3.1. Beta Emitters
    • 7.3.2. Alpha Emitters
    • 7.3.3. Auger Electron Emitters
    • 7.3.4. Brachytherapy Isotopes

8. Nuclear Medicine Radioisotopes Market, by Mode Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous Injection
  • 8.3. Oral Ingestion

9. Nuclear Medicine Radioisotopes Market, by Production Technology

  • 9.1. Introduction
  • 9.2. Nuclear Reactor Production
  • 9.3. Cyclotron Production
  • 9.4. Generator Systems
  • 9.5. Linear Accelerator Production

10. Nuclear Medicine Radioisotopes Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutes
  • 10.3. Diagnostic Imaging Centers
  • 10.4. Hospitals
  • 10.5. Pharmaceutical & Biotechnology Companies

11. Nuclear Medicine Radioisotopes Market, by Disease Area

  • 11.1. Introduction
  • 11.2. Oncology
  • 11.3. Cardiology
  • 11.4. Neurology
  • 11.5. Endocrinology
  • 11.6. Pulmonology
  • 11.7. Nephrology
  • 11.8. Gastroenterology
  • 11.9. Infection And Inflammation

12. Nuclear Medicine Radioisotopes Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Nuclear Medicine Radioisotopes Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. ASEAN
  • 13.6. GCC

14. Nuclear Medicine Radioisotopes Market, by Country

  • 14.1. United States
  • 14.2. China
  • 14.3. Germany
  • 14.4. Japan
  • 14.5. India
  • 14.6. United Kingdom
  • 14.7. France
  • 14.8. Canada
  • 14.9. Italy
  • 14.10. Australia
  • 14.11. Brazil
  • 14.12. South Korea
  • 14.13. Mexico
  • 14.14. Russia
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Bayer AG
  • 16.2. Bracco Imaging SpA
  • 16.3. BWX Technologies Inc
  • 16.4. China Isotope & Radiation Corporation
  • 16.5. Curium NV
  • 16.6. Eckert & Ziegler SE
  • 16.7. GE HealthCare Technologies Inc
  • 16.8. Global Medical Solutions LLC
  • 16.9. Institut National des Radioelements
  • 16.10. Institute of Isotopes Co Ltd
  • 16.11. International Isotopes Inc
  • 16.12. Ion Beam Applications SA
  • 16.13. Isotopia Molecular Imaging Ltd
  • 16.14. ITM Isotope Technologies Munich SE
  • 16.15. JSC Isotope
  • 16.16. Jubilant Pharmova Limited
  • 16.17. Lantheus Holdings Inc
  • 16.18. Nordion Canada Inc
  • 16.19. NorthStar Medical Radioisotopes LLC
  • 16.20. Novartis AG
  • 16.21. NTP Radioisotopes SOC Ltd
  • 16.22. PDRadiopharma Inc
  • 16.23. PharmaLogic Holdings Corp
  • 16.24. RadioMedix Inc
  • 16.25. SHINE Technologies LLC
  • 16.26. Siemens Healthineers AG
  • 16.27. SpectronRx LL
  • 16.28. Telix Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC ISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC ISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC ISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SPECT ISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SPECT ISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SPECT ISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TECHNETIUM-99M MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TECHNETIUM-99M MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IODINE-123 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IODINE-123 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IODINE-123 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THALLIUM-201 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THALLIUM-201 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THALLIUM-201 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GALLIUM-67 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GALLIUM-67 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GALLIUM-67 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INDIUM-111 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INDIUM-111 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INDIUM-111 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PET ISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PET ISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PET ISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FLUORINE-18 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FLUORINE-18 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FLUORINE-18 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARBON-11 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARBON-11 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARBON-11 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NITROGEN-13 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NITROGEN-13 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NITROGEN-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OXYGEN-15 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OXYGEN-15 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OXYGEN-15 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RUBIDIUM-82 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RUBIDIUM-82 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RUBIDIUM-82 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COPPER-64 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COPPER-64 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COPPER-64 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THERAPEUTIC ISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THERAPEUTIC ISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THERAPEUTIC ISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BETA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BETA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BETA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ALPHA EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ALPHA EMITTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUGER ELECTRON EMITTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUGER ELECTRON EMITTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUGER ELECTRON EMITTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRACHYTHERAPY ISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRACHYTHERAPY ISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRACHYTHERAPY ISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTRAVENOUS INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRAVENOUS INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTRAVENOUS INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL INGESTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL INGESTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL INGESTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR REACTOR PRODUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR REACTOR PRODUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR REACTOR PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CYCLOTRON PRODUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CYCLOTRON PRODUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CYCLOTRON PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENERATOR SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENERATOR SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENERATOR SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LINEAR ACCELERATOR PRODUCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LINEAR ACCELERATOR PRODUCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LINEAR ACCELERATOR PRODUCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIAGNOSTIC IMAGING CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIAGNOSTIC IMAGING CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIAGNOSTIC IMAGING CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ENDOCRINOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PULMONOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PULMONOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PULMONOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NEPHROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEPHROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NEPHROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GASTROENTEROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFECTION AND INFLAMMATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTION AND INFLAMMATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFECTION AND INFLAMMATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 184. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 185. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 186. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 187. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 191. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 194. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 195. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 196. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 197. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 231. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 234. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 235. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 236. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 237. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 277. JAPAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 278. JAPAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. JAPAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. JAPAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 281. JAPAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 282. INDIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. INDIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. INDIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 285. INDIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 286. INDIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 287. INDIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 288. INDIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. INDIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. INDIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. INDIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 307. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 308. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 311. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 322. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 323. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 324. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 325. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 326. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 327. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 328. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 329. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 330. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 331. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 332. AUSTRALIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC